.jpg)
In a space of increased innovation in drug delivery, I took a deeper look into the leading products taking the market by storm.
In this episode of Diagnostics Digest, I speak with David Wells, Chief Executive Officer of the Institute of Biomedical Science (IBMS) and Chief NHS Pathologist during COVID-19. Click to listen now.
In a space of increased innovation in drug delivery, I took a deeper look into the leading products taking the market by storm.
In this episode of Diagnostics Digest, I speak with David Wells, Chief Executive Officer of the Institute of Biomedical Science (IBMS) and Chief NHS Pathologist during COVID-19. Click to listen now.
.jpg)
In this episode, I speak to Leigh Fell, CEO at Caritas Neuro Solutions, about carving your niche, the impact of work-life balance, the importance of psychedelic drug discovery and loads more. Click here to listen.
How can we improve diversity and access within the research space, particularly at site level? We asked some site managers in the know.
Are you attracting the very best industry talent to your start-up? For expert advice on how to thrive in today’s life science talent market, watch CM Life Science's latest 30-minute webinar. Click to watch.
In this episode of Diagnostics Digest, a CM Life Science series discussing trends and insights into the diagnostics market, I speak with Beth Cobb, Chief Operating Officer at NOWDiagnostics | NowDx.
In this episode, I speak with Kirk Sudheimer, SVP of BD & Sales at Health Catalyst about collaboration, innovation and transforming the future of healthcare. Click and have a listen.
In this episode, I chat with Grant Neckermann, SVP of Talent at Syapse, about leading an innovative start-up to success through investment in people. Click to hear his thoughts.
In this episode of Lessons from Leaders in Life Science, I spoke with Jen Skeen, COO at renegade.bio, about carving your own path as a woman in science and so much more. Check out her brilliant story.
The data revolution has created a wealth of opportunity in the bioinformatics industry. I caught up with three industry experts to find out what's next for software data in the life sciences industry. Click to find out who.
In this episode of CM Conversations, I speak with Dr. Callie Seaman, company Director, trained medical professional, and experienced medicinal cannabis advocate about the future of the industry in the UK. Click to have a listen.
How have animal diagnostics companies adapted to stay relevant and successful post-pandemic? We explore companies across the industry to find out.
We spoke to Margaret, Chris, Tiffany and Brad about the challenge clinical trials have in becoming more heterogeneous
First, it's one of Boston's 'Best Small Companies To Work For', then it announced a major Labcorp partnership. But how have Weavr Health overcome the challenges of retaining a core company culture when scaling a fast-growing start-up?
Developing and manufacturing drugs is more expensive and complicated than ever before. Many outsource to CDMO's, but which approach truly offers the most value? Click to read more.
Small molecules are now able to target previously ‘undruggable’ conditions, such as cancers and neurological disorders, I discuss how we got here and what it means for the market. Click to read more.
In part two of this discussion, Dennis and I discuss the key barriers for entry for companies expanding into new territories and how to overcome these, whether you're a start-up or established company entering a new market. Click to listen.
In this final part, Dennis and I discuss new technologies to watch in the liquid biopsy market, as well as insights into innovation from behind the scenes at Predicine. Click to listen now.
Predicine With a background in research, pharma and commercial, Dennis gives insight into the true value of liquid biopsy. Click to listen.
Alongside COVID, most sponsors saw a significant shift to a more patient-centric approach in 'decentralized clinical trials'. But what does this mean for the future industry? Click to read more.
This is the first in a new CM Life Science series discussing trends and insights into the diagnostics market. Here I'm joined by Delphine, to discuss European market expansion strategies within the diagnostics space. Click to listen.
.jpg)
Spencer talks to to Vered Caplan, CEO at Orgenesis Inc. about how their Point Of Care (POC) Platform aims to shape the Cell and Gene Therapies (CGT) ecosystem and market. Click here to listen.
Bioinformatics established its worth right from the start of the pandemic, solving complex real-life scientific problems with rapid effect. What does this leap forward mean for future life science discoveries? Click to read more.
As the Theranos and Holmes trial finally comes to a close, what has been the effect of the CEO’s 15 years of fraudulent tenure on the diagnostics industry?
African Swine Fever has been rife across key global swine markets for some years, but what does this mean for the wider market and its future? Click to read more.
As small-molecule CDMOs pivot their businesses to meet the demands of the life science sector, I spoke with CEO & Founder Tia Lyles-Williams to find out what this really means for the industry. Click to find out more.
We talk to Tim Roberts, who’s Chief Commercial Officer at PCI Pharma Services. Click to listen to his experiences in and predictions for the clinical trial supply market.
Cannabis legalisation is the hot topic of many European politicians, but once the race begins who will be in it to win? Click to read more.
In the wake of COVID, NGS technology is entering one of the most productive, and exciting, times the market has ever seen. Click to find out more.
The WHO approval of the malaria vaccine will have huge industry impact, but the logistics are often overlooked. Click to read more.
